EATG » Hepatitis

Hepatitis

Hepatitis C drug market: analysis

Two publications in Bloomberg Gadfly and MD Magazine analyze the hepatitis C drug market. Access the publications here and here.

Viekira Pak safe for patients with HCV, Child-Pugh A cirrhosis

Patients with hepatitis C and Child-Pugh A cirrhosis had similar rates of treatment-related adverse events and lower rates of hepatic decompensation after treatment with Viekira Pak compared with untreated patients,…

Is HCV drug development nearing its end?

Two new FDA approvals fill medical gaps, but access to treatment remains a challenge The FDA recently approved two new combination regimens for hepatitis C, raising the question of whether…

Replicor announces publication of its REP 301 study in HBV/HDV co-infection

MONTREAL, September 28, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus…

8 top stories on injection drug users, HIV/HCV coinfection

At the recent International Symposium on Hepatitis Care in Substance Users, researchers presented new data on injection drug users and their unique risk factors for hepatitis C infection and transmission,…

Epidemiological update: hepatitis A outbreak in the EU/EEA mostly affecting MSM

Since the last rapid risk assessment on this multi-country hepatitis A outbreak, 19 EU/EEA countries (Austria, Belgium, Denmark, Estonia, Finland, France, Greece, Ireland, Italy, Latvia, Luxembourg, Malta, the Netherlands, Norway,…

Merck discontinues MK-3682B and MK-3682C development programs

Company to focus on maximizing the potential of ZEPATIER ® (elbasvir and grazoprevir) KENILWORTH, N.J., September 29, 2017--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today…

Arrowhead data reveal important considerations for future hepatitis B treatment

Results may guide new clinical approaches, Science Translational Medicine study shows PASADENA, Calif., Sept. 27, 2017 -- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced results from studies of ARC-520, a…

Arbutus announces topline results for ARB-1467 Phase II Cohort 4 for the treatment of hepatitis B

Detailed data to be presented at AASLD in October VANCOUVER, British Columbia and WARMINSTER, Pa., Sept. 25, 2017 -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic…

Most patients with HCV genotypes 2, 4, 5, 6 achieve SVR with Mavyret

Most patients with hepatitis C genotype 2, 4, 5 or 6 who received Mavyret for 8 weeks achieved sustained virologic response with a high safety profile, according to results from…